BNET Industries
Market Cap:$32.4M
Last Fiscal Year Sales:$1.3M
- Public
- US
Dow Jones Description
Arrowhead Research Corporation is a nanotechnology company structured to bring together a diverse set of technologies, a broad suite of intellectual property, and some of the most respected minds in this dynamic field. There are three strategic components to Arrowhead's business model: - The Commercialization Program - Arrowhead forms or acquires majority-owned subsidiary companies pursuing products based on nanotechnology in high growth technology markets. - R&D Pipeline - Arrowhead funds nanoscience research at universities in exchange for the exclusive right to license the technology. - The IP Toolbox - Arrowhead acquires, licenses, and sublicenses intellectual property in nanotechnology.
Number of Employees 68
Contact Information
201 S Lake Ave Ste 703
Pasadena, California 91101-3074
(626) 304-3400
Peer Companies
NAICS Code : 541710
Recent Events
-
Arrowhead Gets Nasdaq Deficiency Notice Related To Minimum Bid Price - Quick Facts
-
Arrowhead Receives NASDAQ Deficiency Notice Related to Minimum Bid Price
-
Space Elevator Could Be Operational By 2020
-
Arrowhead Reports Third Quarter Fiscal 2009 Financial Results
-
Arrowhead CFO To Step Down - Update
-
BRIEF-Arrowhead says CFO Paul Mcdonnel intends to resign
-
Arrowhead's ARWR CFO, McDonnel, to Resign; Announces Private Placement of $2M
-
Arrowhead Subsidiary Enters into Licensing Pact with Cerulean Pharma
News & Analysis
Filter by
arrowhead research corp. - All News and Analysis
Arrowhead Research Corp. F3Q09 (Qtr End 30/06/09) Earnings Call Transcript
Question-and-Answer SessionOperator Operator Instructions There do not appear to be any questions at this time. With that this will conclude today’s conference. We do thank you very much for your participation. If you would like to listen to a replay of today’s conference, you could do so by...
Arrowhead Research Corp. F3Q09 (Qtr End 30/06/09) Earnings Call Transcript
Arrowhead Research Corp. ARWR F3Q09 Earnings Call August 10, 2009; 04:30 pm ET
Arrowhead Research Corporation Q1 2009 Earnings Call Transcript
Question-and-Answer SessionOperator (Operator's instruction) Your first question comes from the line of Bill Boutin - Indusino Capital Management. Bill Boutin - Indusino Capital Management Real quick, could you guys go over again your plan, just on the Company, until the end of the year? Dr. Christopher Anzalone Sure, we...
Arrowhead Research Corporation F4Q08 (Qtr End 09/30/08) Earnings Call Transcript
Question-and-Answer Session Operator Operator Instructions. We do have a question from Bill Boutin with Indusino Capital Management. Bill Boutin - Indusino Capital Management Just a couple of quick questions. First one is on the balance sheet. Given that you raised money in Arrowhead itself and you...
Arrowhead Announces the Appointment of Dr. Mauro Ferrari to Its New Board of Advisors
PASADENA, Calif. -- Arrowhead Research Corporation (Nasdaq:ARWR) announced today the appointment of Dr. Mauro Ferrari to its newly established Board of Scientific Strategy. He is one of the most well-known experts in leveraging nanotechnology to treat and diagnose cancer. Dr. Ferrari will serve as a Director of Scientific Strategy and...
Arrowhead Announces Option Grant to CEO under NASDAQ Marketplace Rule 4350
PASADENA, Calif. -- Arrowhead Research Corporation (Nasdaq: ARWR) announced today that in accordance with NASDAQ Marketplace Rule 4350i(1)Aiv, the Compensation Committee of the Board of Directors approved an inducement grant of a stock option to Christopher Anzalone, Arrowhead's new President and Chief Executive Officer. On December 3, 2007, Dr. Anzalone...
Arrowhead Subsidiary, Unidym, Closes $10.4 Million Financing Led by Financial and Strategic Institutions
PASADENA, Calif. -- Arrowhead Research Corporation (Nasdaq:ARWR), announced today that majority owned subsidiary, Unidym, Inc., has completed a $10.4 million Series C financing. Several financial institutions participated in the round, along with strategic investors Tokyo Electron Ventures and Battelle Memorial Institute. Arrowhead made a $3 million follow on investment. ...
Insert Therapeutics' Lead Anti-Cancer Compound is Highlighted in Public Television Documentary
PASADENA, Calif. -- Insert Therapeutics, Inc., a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), announced today that its lead anti-cancer compound, IT-101, will be featured in a public television documentary series produced by Thirteen/WNET New York and the California Institute of Technology Caltech. IT-101 is an experimental drug now...
FUNDING.
Nanosys Raises $40 Million Private Equity Funding. Nanosys, Inc.(Palo Alto, CA), a private company developing inorganic semiconductor nanocrystal-enabled products, has recently raised approximately $40 million in a private equity financing. This financing was led by El Dorado Ventures, other existing investors and several new ...
Naked Short Web Site announces ARWR, KNTA, SDA, VLCCF, PUFF, IYXI have been removed from threshold lists today.
M2 PRESSWIRE-27 May 2005-BUYINS.NET: Naked Short Web Site announces ARWR, KNTA, SDA, VLCCF, PUFF, IYXI have been removed from threshold lists todayC1994-2005 M2 COMMUNICATIONS LTD RDATE:27052005 BUYINS.NET, www.buyins.net, announced today that these select companies have been removed from the NASDAQ, AMEX...
- 1
- 2
Decision Makers
| Name (plus bio) | Position |
|---|---|
| R. Bruce Stewart | CEO |
| Jeremy Heidel | Chief Scientific Officer and Vice President, Research & Development |
| Paul McDonnel | Chief Financial Officer |
| Ralph J Harms | Chief Financial Officer |
| Thomas Haag | Chief Patent Officer |
| James Hamilton | Vice President |
| Jane Davidson | Vice President, Operations |
| John C Miller | Vice President of Business Development |
| Mark Tilley | Vice President, Advanced Materials |
| Virginia Dadey | Vice President, Ir |
| Dr Harry Atwater | Founder of Aonex |
| Mark Davis | Founder |
| James M. Phillips | Secretary |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Chad A. Mirkin | Board of Directors |
| Charles P. McKenney | Board of Directors |
| LeRoy T. Rahn | Board Member |
| Mauro Ferrari | Board of Directors |
| Russ Lebovitz | Board of Directors |
R. Bruce Stewart is the founder, director, and Executive Chairman of the Board of Arrowhead Research. A life-long entrepreneur, Mr. Stewart has started and funded over eighteen companies and has taken several of them to the public markets. His capital market experience spans thirty years and he has raised substantial capital for both public and private companies. He is known for his success in building value for shareholders and innovating novel strategies in corporate finance. Prior to founding Arrowhead Research, Mr. Stewart founded Acacia Research Corporation which he took public in 1995. During Mr. Stewart’s eight-year tenure, Acacia built a portfolio of subsidiary companies operating in the areas of biotechnology, media technology licensing, direct marketing and early internet applications and reached a market cap of close to $1 billion. Mr. Stewart gained much of his knowledge and experience in corporate finance as President of Annandale Securities from 1977 to 1992, an investment banking firm and registered broker dealer. He structured innovative financing vehicles which have since become industry standard. Early in 2003, Mr. Stewart brought the sum of his knowledge and experience to the field of nanotechnology. In forming Arrowhead Research Corporation, he has combined his access to capital and his talent for finding early-stage technology with commercial potential with the belief that the path to the future goes through nanotech. In the short time Arrowhead has been operating, Mr. Stewart’s vision has resulted in a well-financed company partnered with some of the most respected minds in the field.
| Organization | Position | Status |
|---|---|---|
| Arrowhead Research Corporation | CEO | Current |
| Arrowhead Research Corporation | Founder | Current |
| Unidym Inc | Chairman of The Board | Current |
| Arrowhead Research Corporation | Chairman | Current |
| Insert Therapeutics, Inc. | Board of Directors | Current |
| Calando Pharmaceuticals, Inc | Board of Directors | Current |
| Unidym Inc | Chief Executive Officer | Former |
| Acacia Research Corporation | Founder | Former |
| Northwestern University | MBA | Former |
| Organization | Position | Status |
|---|---|---|
| Arrowhead Research Corporation | Chief Scientific Officer and Vice President, Research & Development | Current |
| Insert Therapeutics, Inc. | Vice President Research & Development and Chief Scientific Officer Oligonucleotide Delivery | Current |
| California Institute of Technology | Ph.D. Degrees In Chemical Engineering | Former |
| California Institute of Technology | M.S. | Former |
Paul McDonnel was appointed Chief Financial Officer of Arrowhead in January 2008. Mr. McDonnel held the position of Vice President, Finance and Accounting of the Company since 2006. He has served in a variety of executive-level finance, accounting and operational positions. From 2003 until 2005, Mr. McDonnel served as CEO and CFO of Quality Imaging Products, an Irvine, California-based remanufacturer of toner cartridges, which was sold in 2005 to Printing Technology, Inc. From 1999 to 2003, he was CFO at Instashred Security Services LLC, a provider of shredding services across North America, until its sale to Recall Secured Destruction Services, Inc., when he became Senior Operations Manager for California. During his 26-year career, he also served as the CFO of Reid Plastics, Inc. and Trojan Enterprises, Inc. and worked closely with several private equity groups in connection with merger and acquisition transactions. Mr. McDonnel is a CPA and began his career in the Los Angeles office of Arthur Andersen & Co. Mr. McDonnel received his masters degree in management accounting and his bachelors degree in accounting from Brigham Young University.
| Organization | Position | Status |
|---|---|---|
| Arrowhead Research Corporation | Chief Financial Officer | Current |
| Trojan Enterprises Inc | Cfo | Former |
| Organization | Position | Status |
|---|---|---|
| Arrowhead Research Corporation | Chief Financial Officer | Current |
Thomas Haag, Ph.D., J.D. is the General Counsel and Chief Patent Officer of Arrowhead Research Corporation. Previously, Dr. Haag was in private practice in the Washington D.C. offices of Kenyon & Kenyon LLP and McDermott Will & Emery LLP. He has extensive experience in advising newly formed companies in establishing, developing and leveraging their patent portfolios. His expertise includes negotiating and drafting intellectual property licenses, conducting IP due diligence investigations, as well as coordinating IP and FDA regulatory strategies. He also has experience in patent litigation in the U.S. and UK, before the ITC and the European Patent Office. Dr. Haag received his B.S. in Biology and Ph.D. in Molecular, Cell & Developmental Biology from UCLA where he was an NIH Predoctoral Fellow in Genetic Mechanisms. He graduated from The George Washington University Law School with honors, receiving the ABA/BNA Award for Excellence in the Study of Intellectual Property Law. He is admitted to practice before the USPTO, in New York and in the District of Columbia. He is registered as California In-House Counsel.
| Organization | Position | Status |
|---|---|---|
| Arrowhead Research Corporation | Chief Patent Officer | Current |
Array
| Organization | Position | Status |
|---|---|---|
| Tego Biosciences Corporation | Vice President Medical Technologies | Current |
| Arrowhead Research Corporation | Vice President | Current |
| Southern Pines Equine Associates | Owner | Current |
| The Ohio State University | MD Degree | Former |
| The Ohio State University | Bachelor's Degree | Former |
| Miami University | Former |
| Organization | Position | Status |
|---|---|---|
| Tego Biosciences Corporation | Vice President, Secretary | Current |
| Arrowhead Research Corporation | Vice President, Operations | Current |
| Acacia Research Corporation | Vice President, Shareholder Relations | Former |
| Hood College | B.A. in Biology | Former |
| Organization | Position | Status |
|---|---|---|
| Unidym Inc | Vice President, Business Development | Current |
| Tego Biosciences Corporation | Vice President of Business Development | Current |
| Arrowhead Research Corporation | Vice President of Business Development | Current |
| Nanotechnology Law & Business | Managing Editor | Current |
| Nanotechnology Law & Business | Founder | Former |
| Stanford Law School | Former |
Dr. Mark Tilley is Chief Executive Officer of Unidym. He also serves as Vice President, Advanced Materials of Arrowhead Research Corporation (NASDAQ: ARWR). Prior to joining Arrowhead, he spent 9 years at DSM N.V.; a $12B Netherlands based specialty performance materials and life science company. Most recently, he served as Senior Investment Manager with DSM's Corporate Venturing Arm and served on the boards of CreAgri, Novomer, Van Technologies, Harland Medical Systems and InMat. Prior to his work with DSM Ventures, Dr. Tilley was Vice President of Research and Business Development for DSM Desotech, an operating division of DSM that is the global market leader in fiber optic coatings and stereo lithographic resins. During his tenure, he led marketing and technical teams, and built a nano-enabled flat panel displays materials business that was acquired by JSR in 2005. Dr. Tilley also co-founded Kriya Materials B.V., a venture capital backed nano-materials and coatings company based in the Netherlands.
| Organization | Position | Status |
|---|---|---|
| Unidym Inc | Chief Executive Officer | Current |
| Arrowhead Research Corporation | Vice President, Advanced Materials | Current |
| GE Plastics | Current | |
| Ngen Partners, LLC | Current | |
| DSM Desotech Inc. | Vice President of Research and Business Development | Former |
| Creagri, Inc. | Board of Directors | Former |
| Novomer, Inc. | Board of Directors | Former |
| Harland Medical Systems, LLC | Board of Directors | Former |
| Inmat Inc | Board of Directors | Former |
| North Dakota State University | Ph.D. In Photochemistry | Former |
| Organization | Position | Status |
|---|---|---|
| Tego Biosciences Corporation | Vice President Investor Relations | Current |
| Arrowhead Research Corporation | Vice President, Ir | Current |
| Maxim Group, LLC | Senior Vice President of Institutional Sales | Former |
| Gruntal & Co. | vice president | Former |
| Purdue University | B.S. in Nutritional Science | Former |
| Organization | Position | Status |
|---|---|---|
| Arrowhead Research Corporation | Founder of Aonex | Current |
| California Institute of Technology | Professor of Applied Physics and Materials Science | Former |
| The Boston Consulting Group, Inc. | strategy consultant | Former |
| Lawrence Livermore National Laboratory | team leader | Former |
| California Institute of Technology | Ph.D. | Former |
| Massachusetts Institute of Technology | bachelor's and master's degrees in engineering | Former |
| Harvard Business School | master's degree in business administration | Former |
Mark Davis, Ph.D. is the Warren and Katharine Schlinger Professor of Chemical Engineering and Executive Officer of Chemical Engineering at California Institute of Technology. The founder of Insert Therapeutics, Inc. and Calando Pharmaceuticals, Inc., Dr. Davis is a Member of the National Academy of Engineering and a recipient of numerous awards including the prestigious Alan T. Waterman Award, given by the National Science Foundation annually to only one scientist in the United States across all disciplines. Dr. Davis was the first engineer to win this award for his work in rationally designed materials. Dr. Davis earned his B.S., M.S. and Ph.D. degrees in Chemical Engineering and holds over 25 patents, has published more than 250 papers and has presented over 400 seminars throughout the world.
| Organization | Position | Status |
|---|---|---|
| Calando Pharmaceuticals, Inc | Founder | Current |
| Insert.Com | Founder | Current |
| Arrowhead Research Corporation | Founder | Current |
| Insert Therapeutics, Inc. | Founder | Current |
| Insert Therapeutics, Inc. | Board of Directors | Current |
| Arrowhead Research Corporation | Board of Directors | Current |
| California Institute of Technology | Executive Officer of Chemical Engineering | Former |
| Organization | Position | Status |
|---|---|---|
| Arrowhead Research Corporation | Secretary | Current |
| Arrowhead Research Corporation | Secretary | Former |
| Organization | Position | Status |
|---|---|---|
| NanoInk, Inc. | Founder | Current |
| Nsti | Professor, Department of Chemistry, Director, International Institute for Nanotechnology | Current |
| Pittcon | Current | |
| Arrowhead Research Corporation | Board of Directors | Current |
| NanoInk, Inc. | Board of Directors | Current |
| NanoInk, Inc. | Director, Conferences | Former |
| Dickinson College | Doctorate | Former |
| The Pennsylvania State University | Ph.D. Degree In Chemistry | Former |
| Dickinson College | B.S. Degree | Former |
| Aaas.Com | Fellow | Former |
Charles P. McKenney has maintained a government affairs law practice in Pasadena, California since 1989, representing businesses and organizations in their relations with government regarding their obligations under state and local land use and trade practices laws. From 1973 through 1989, he served as Attorney for Corporate Government Affairs for Sears, Roebuck and Co., helping organize and carry out Sears' Western state and local government relations programs. Mr. McKenney has served two terms on the Pasadena, California City council, on several city boards and committees in Pasadena, including three city Charter Reform Task Forces.
| Organization | Position | Status |
|---|---|---|
| Arrowhead Research Corporation | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Bell Telephone Laboratories | Member | Current |
| Christie , Parker & Hale, Llp | Of Counsel | Current |
| Pasadena Angels, Inc. | Team Member | Current |
| Arrowhead Research Corporation | Board Member | Current |
| Christie , Parker & Hale, Llp | Partner | Former |
| University of Southern California | Electrical Engineering degree | Former |
| New York University | Law degree | Former |
| Siemens AG | Member | Former |
Dr. Mauro Ferrari serves as a Professor & Director, Center for NanoMedicine, Brown Foundation Institute of Molecular Medicine, Chairman, Department of Biomedical Engineering, University of Texas Health Science Center at Houston, Professor of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Professor of Bioengineering, Rice University, and President of the Alliance for NanoHealth, Houston TX. Dr. Ferrari received a Ph.D. in Mechanical Engineering from U.C. Berkeley. Dr. Ferrari is a founder of biomedical nano/micro-technology in biomedical applications with more than 160 peer-reviewed journal articles, six books, more than 20 issued patents and about thirty more pending in the US and internationally. His career research and development portfolio totals over $50 million. Dr. Ferrari served as Special Expert on Nanotechnology at the National Cancer Institute in 2003-2005, providing leadership into the establishment of the NCI's Alliance for Nanotechnology.
| Organization | Position | Status |
|---|---|---|
| Arrowhead Research Corporation | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Arrowhead Research Corporation | Board of Directors | Current |
Executive News
-
Arrowhead Research Corp. F3Q09 (Qtr End 30/06/09) Earnings Call Transcript


